Cargando…
PPARα Modulation-Based Therapy in Central Nervous System Diseases
The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of dam...
Autores principales: | Lee, Deokho, Tomita, Yohei, Allen, William, Tsubota, Kazuo, Negishi, Kazuno, Kurihara, Toshihide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622664/ https://www.ncbi.nlm.nih.gov/pubmed/34833044 http://dx.doi.org/10.3390/life11111168 |
Ejemplares similares
-
PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020) -
Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy
por: Tomita, Yohei, et al.
Publicado: (2021) -
Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?
por: Lee, Deokho, et al.
Publicado: (2022) -
Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion
por: Lee, Deokho, et al.
Publicado: (2021) -
Molecular and Cellular Regulations in the Development of the Choroidal Circulation System
por: Imanishi, Satoshi, et al.
Publicado: (2023)